NightHawk Biosciences, Inc. (NHWK) |
|
0.54 0.005 (0.93%)
|
09-27 11:12 |
|
Open: |
0.55 |
Pre. Close: |
0.535 |
|
High:
|
0.565 |
Low:
|
0.54 |
|
Volume:
|
9,830 |
Market Cap:
|
14(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 10:48:30 AM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 0.75 One year: 0.85 |
| Support: |
Support1: 0.5 Support2: 0.42 |
| Resistance: |
Resistance1: 0.64 Resistance2: 0.73 |
| Pivot: |
0.57  |
| Moving Average: |
MA(5): 0.54 MA(20): 0.59
MA(100): 0.65 MA(250): 0.94 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 13.5 %D(3): 7.3 |
| RSI: |
RSI(14): 40.8 |
| 52-week: |
High: 1.89 Low: 0.5 |
| Average Vol(K): |
3-Month: 43 (K) 10-Days: 36 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NHWK ] has closed above bottom band by 22.9%. Bollinger Bands are 16.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.6 - 0.6 |
0.6 - 0.6 |
|
Low:
|
0.5 - 0.51 |
0.51 - 0.51 |
|
Close:
|
0.53 - 0.54 |
0.54 - 0.54 |
|
Company Description |
|
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina. |
Headline News |
Tue, 26 Sep 2023
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are ... - Investing.com UK
Mon, 14 Aug 2023
NightHawk Biosciences Provides Q2 2023 Business Update - GlobeNewswire
Wed, 14 Jun 2023
Why Is Eastside Distilling (EAST) Stock Down 25% Today? - InvestorPlace
Wed, 14 Jun 2023
Why Is Cineverse (CNVS) Stock Down 24% Today? - InvestorPlace
Wed, 14 Jun 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Wed, 14 Jun 2023
Why Is NightHawk Biosciences (NHWK) Stock Up 26% Today? - InvestorPlace
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
